RESUMEN
The neuroprotective effects of a systemically active, highly selective, corticotropin-releasing factor-1 (CRF1) receptor antagonist, R121920 ((7-(dipropylamino)-2,5-dimethyl-3- [2-(dimethylamino)-5-pyridyl] pyrazolo [1,5-a] pyrimidine), was assessed in two rat models of permanent focal cerebral ischemia, where the middle cerebral artery (MCA) was occluded either through the subtemporal approach or using the intraluminal suture technique. R121920 rapidly crossed the blood-brain barrier after intravenous (IV) bolus administration (10 mg/kg), with peak brain concentrations at 5 minutes (2.26 +/- 0.40 microg/mL), which were approximately 2-fold greater than those in plasma (0.98 +/- 0.24 microg/mL). Treatment with R121920 (10 mg/kg IV followed by 5 mg/kg subcutaneously at hourly intervals for 4 hours) significantly (P < 0.001) reduced total (by 40%) and cortical (by 37%) infarct volume at 24 hours after subtemporal MCA occlusion (MCAO). In the intraluminal suture MCAO model, IV administration of R121920 (10 mg/kg) at the time of ischemia onset (and at multiple times thereafter) reduced both hemispheric infarct volume (by 34%, P < 0.001) and brain swelling (by 50%, P < 0.001) when assessed at 24 hours. In this model of focal ischemia, significant reduction (P < 0.05) in both outcome measures was obtained when R121920 administration was delayed up to 1 hour after MCAO. These results further define the antiischemic properties of selective CRF 1 antagonists in two experimental models of permanent focal cerebral ischemia.
Asunto(s)
Isquemia Encefálica/fisiopatología , Fármacos Neuroprotectores/farmacología , Receptores de Hormona Liberadora de Corticotropina/antagonistas & inhibidores , Animales , Edema Encefálico/fisiopatología , Edema Encefálico/prevención & control , Masculino , Arteria Cerebral Media/patología , Ratas , Ratas Sprague-DawleyRESUMEN
The effect of a typical 5-day chemotherapy treatment with cisplatin (20-40 mg/m2 per day) and 5-fluorouracil (5-FU, 1 gm/m2 per day) on the pharmacokinetics of ondansetron was investigated. Twenty cancer patients received 8 mg of ondansetron in three periods, including an oral tablet on day 1, an intravenous infusion on day 4, and an oral tablet on day 5. Absolute bioavailability after the oral dosing on day 1 was 87.5 +/- 31.3%, and on day 5 was 85.2 +/- 22.1% (P > .05). Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively. These values were not significantly different (P > .05). In summary, this study showed that cisplatin and 5-FU did not significantly alter the pharmacokinetics of oral ondansetron in cancer patients during the 5 days of chemotherapy. Oral bioavailability of ondansetron appeared to be greater in cancer patients than in healthy subjects.
Asunto(s)
Cisplatino/farmacología , Fluorouracilo/farmacología , Neoplasias/metabolismo , Ondansetrón/farmacocinética , Administración Oral , Adolescente , Adulto , Disponibilidad Biológica , Cisplatino/uso terapéutico , Femenino , Fluorouracilo/uso terapéutico , Semivida , Humanos , Infusiones Intravenosas , Masculino , Neoplasias/tratamiento farmacológico , Ondansetrón/administración & dosificación , ComprimidosRESUMEN
Circadian variations in hepatic glutathione-S-transferase and glutathione peroxidase activities were found in male Swiss-Webster mice maintained under a 12/12 lighting schedule (L: 06.00-18.00 h) for 3 weeks prior to use. Hepatic glutathione-S-transferase activity was significantly elevated during the dark phase as compared to the light phase. The glutathione peroxidase activity, using two different substrates, was biphasic in nature. Using cumene hydroperoxide, the enzyme activity was significantly elevated at 18.00 and 06.00 h; nadirs occurred at 10.00, 14.00 and 22.00 h. Using hydrogen peroxide as the substrate, enzyme activity was greatest at 14.00 and 06.00 h; nadirs occurred at 10.00 and 22.00 h. Glutathione concentration also varied in a circadian manner with peak levels occurring between 06.00 and 10.00 h and the nadir occurring at 18.00 h. These studies have shown that glutathione levels and two enzymes utilizing glutathione as a cosubstrate vary in a similar circadian manner, with the highest values primarily occurring during the dark phase. Thus, these results may have considerable toxicological importance.
Asunto(s)
Ritmo Circadiano , Glutatión Peroxidasa/metabolismo , Glutatión Transferasa/metabolismo , Hígado/enzimología , Animales , Luz , Masculino , RatonesRESUMEN
Ondansetron is a competitive serotonin 5-HT3 receptor blocker that has proved useful in the prevention of emesis due to cisplatin and other cancer chemotherapeutic agents. In a randomized, open-label, crossover study in 24 healthy male subjects, the relative bioavailability of a single 8-mg tablet was compared with that of an 8-mg solution using the two one-sided t-tests. The tablet and solution formulations were bioequivalent, as confirmed by similarities in mean Cmax (26.3 vs 27.7 ng/mL), Tmax (1.79 vs 1.70 h), and AUC (166.0 vs 167.3 ng.h/mL) values. In another randomized, open-label, crossover study in 12 healthy male subjects, the bioavailability of an 8-mg ondansetron tablet administered 5 min after a standard meal was slightly but significantly greater than in fasted subjects, as indicated by comparative mean AUC values [201.4 ng.h/mL (fed) vs 172.5 ng.h/mL (fasted)]. Coadministration of a magnesium hydroxide/aluminum hydroxide antacid did not affect the bioavailability of the ondansetron tablet.
Asunto(s)
Antiácidos/farmacología , Ondansetrón/administración & dosificación , Ondansetrón/farmacocinética , Absorción , Administración Oral , Adulto , Disponibilidad Biológica , Química Farmacéutica , Estudios Cruzados , Interacciones Farmacológicas , Ayuno , Alimentos , Humanos , Masculino , Ondansetrón/farmacología , Soluciones , ComprimidosRESUMEN
This study was designed to study the in vitro metabolism of indiplon, a novel hypnotic agent, and to assess its potential to cause drug interactions. In incubations with pooled human liver microsomes, indiplon was converted to two major, pharmacologically inactive metabolites, N-desmethyl-indiplon and N-desacetyl-indiplon. The N-deacetylation reaction did not require NADPH, and appeared to be catalyzed by organophosphate-sensitive microsomal carboxylesterases. The N-demethylation of indiplon was catalyzed by CYP3A4/5 based on the following observations: (1) the sample-to-sample variation in N-demethylation of indiplon ([S] = 100 microM) in a bank of human liver microsomes was strongly correlated with testosterone 6beta-hydroxylase (CYP3A4/5) activity (r(2) = 0.98), but not with any other CYP enzyme; (2) recombinant CYP1A1, CYP1A2, CYP3A4, CYP3A5 and CYP3A7 had the ability to catalyze this reaction; (3) the N-demethylation of indiplon was inhibited by CYP3A4/5 inhibitors (ketoconazole and troleandomycin), but not by a CYP1A2 inhibitor (furafylline). In pooled human liver microsomes, indiplon exhibited a weak capacity to inhibit CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4/5 and carboxylesterase (p-nitrophenylacetate hydrolysis) activities (IC50 >/= 20 microM). Clinical data available on indiplon support the conclusions of this paper that the in vitro metabolism of indiplon is catalyzed by multiple enzymes, and indiplon is a weak inhibitor of human CYP enzymes.
Asunto(s)
Benzodiazepinas/farmacología , Benzodiazepinas/farmacocinética , Hipnóticos y Sedantes/farmacología , Hipnóticos y Sedantes/farmacocinética , Tiofenos/farmacología , Tiofenos/farmacocinética , Hidrolasas de Éster Carboxílico/antagonistas & inhibidores , Inhibidores Enzimáticos del Citocromo P-450 , Interacciones Farmacológicas/fisiología , Humanos , Microsomas Hepáticos/efectos de los fármacos , Microsomas Hepáticos/enzimologíaRESUMEN
A model for predicting the magnitude of error (% Err) in measuring tissue concentrations of a compound that have not been corrected for residual blood in the tissue was previously developed. The model was tested using data for phencyclidine tissue distribution in the rat. It is shown that % Err may be expressed as a function of volume fraction of blood in tissue (VF)B and tissue-to-blood distribution coefficient. Correction for residual blood is important when the volume fraction of the blood in the tissue is large and when the compound is not taken up substantially by the tissue. On the other hand, a correction may not be necessary when (VF)B is small and uptake of the compound into the tissue is substantial.
Asunto(s)
Modelos Biológicos , Farmacocinética , Fenciclidina/farmacocinética , Animales , Radioisótopos de Cromo , Masculino , Fenciclidina/sangre , Ratas , Ratas Endogámicas F344RESUMEN
The pharmacokinetics of a single dose of ranitidine 50 mg iv were determined in ten normal-weight and ten morbidly obese (greater than 90 percent ideal body weight) age-matched female subjects. No significant difference between normal and obese subjects was found in ranitidine peak serum concentration, volume of distribution, clearance, and elimination rate constant. Ranitidine volume of distribution and clearance were significantly smaller in the obese subjects per kilogram of total body weight (1.45 vs. 0.80 L/kg and 0.59 vs. 0.33 L/h/kg, respectively; p less than 0.001) but not when normalized to ideal body weight (1.65 vs. 1.45 L/kg and 0.68 vs. 0.59 L/h/kg). We conclude that obese patients receiving ranitidine therapy should be treated with standard dosages or dosages based on ideal body weight.
Asunto(s)
Obesidad Mórbida/metabolismo , Ranitidina/farmacocinética , Adulto , Femenino , Semivida , Humanos , Inyecciones Intravenosas , Ranitidina/administración & dosificaciónRESUMEN
The disposition of butylbenzyl phthalate (BBP), a widely used plasticizer, was evaluated after oral and iv administration to rats. Male Fischer-344 rats were dosed with [14C]BBP at 2, 20, 200, or 2000 mg/kg po or 20 mg/kg iv to determine the effects of dose on rates and routes of excretion. In 24 h, 61-74% of the dose was excreted in the urine and 13-19% in the feces at 2-200 mg/kg. At the 2000-mg/kg dose, 16% of the 14C was excreted in the urine and 57% in the feces. Urinary 14C was composed of monophthalate derivatives (MP: 10-42% of the dose) and glucuronides of these monophthalate derivatives (2-21% of the dose). At 4 h after iv administration of BBP (20 mg/kg), 53-58% of the dose was excreted in the bile of anesthetized rats. No parent compound was found in the bile, but monobutyl phthalate-glucuronide and monobenzyl phthalate-glucuronide (26% and 13% of the dose, respectively) and trace amounts of free monoesters (2% of the dose) and unidentified metabolites (14% of the dose) were present. Although BBP is an asymmetric diester with the potential of forming equal amounts of monobutyl phthalate (MBuP) and monobenzyl phthalate (MBeP), larger quantities of MBuP were formed (MBuP = 44% versus MBeP = 16% of the dose). The half-lives of BBP, MP, and total 14C in blood (20 mg/kg, iv) were 10 min, 5.9 h, and 6.3 h, respectively. This study indicates that BBP is rapidly metabolized and that the major route of excretion of metabolites is biliary. These metabolites are reabsorbed and ultimately eliminated in the urine.
Asunto(s)
Bilis/metabolismo , Ácidos Ftálicos/metabolismo , Administración Oral , Animales , Bilis/análisis , Radioisótopos de Carbono , Cromatografía Líquida de Alta Presión , Heces/análisis , Inyecciones Intravenosas , Cinética , Masculino , Ácidos Ftálicos/orina , Ratas , Ratas Endogámicas F344 , Distribución TisularRESUMEN
Experiments were conducted to examine the effects of changes in lighting schedules and food consumption on circadian rhythms in acetaminophen lethality and hepatic glutathione levels in male mice. Under a normal lighting schedule (light: 06.00-18.00 h), male mice exhibited a circadian rhythm in acetaminophen lethality (peak: 18.00 h; nadir: 06.00, 10.00 h) and an inverse rhythm in hepatic glutathione concentrations (peak: 06.00, 10.00 h; nadir: 18.00 h). Under a reversed lighting schedule (light: 18.00-06.00 h) the glutathione rhythm was reversed and the rhythm in acetaminophen lethality was altered showing greater sensitivity to the drug. Under continuous light, there was a shift in the acetaminophen lethality and the hepatic glutathione rhythms. Under continuous dark, both rhythms were abolished. Under a normal lighting regimen, hepatic glutathione levels were closely correlated with food consumption; i.e., both were increased during the dark phase and decreased during the light phase. Fasting the mice for 12 h abolished the rhythms in acetaminophen lethality and hepatic glutathione levels; moreover, the lethality was increased and the hepatic glutathione levels were decreased. These experiments show that both lighting schedules and feeding can alter the circadian rhythms in acetaminophen lethality and hepatic glutathione levels in male mice.
Asunto(s)
Acetaminofén/toxicidad , Ritmo Circadiano , Animales , Dieta , Glutatión/metabolismo , Iluminación , Masculino , Ratones , Factores de TiempoRESUMEN
A circadian rhythm in the toxicity of acetaminophen administered at different times of the day was exhibited in male mice. Peak lethality (70% dead) occurred at 1800 hr and nadir lethality (10% dead) occurred at 1000 hr. Hepatic nonprotein sulfhydryl (NPS) concentrations also varied in a circadian manner and were found to exhibit an inverse relationship to the acetaminophen lethality rhythm, with the highest hepatic concentrations occurring at 1000 hr and the lowest concentrations occurring at 1800 hr. At 1800 hr when acetaminophen lethality was greatest and NPS levels the lowest, more reactive acetaminophen metabolites were found covalently bound to hepatic macromolecules as compared to those bound at 1000 hr when NPS levels were highest and acetaminophen lethality was lowest. Hepatic cytochrome P-450 levels measured at these two daily time periods did not differ. The plasma half-life of acetaminophen was significantly decreased at the 1000 hr time period as compared to the 1800 hr time period. These findings suggest that the normal daily changes in NPS levels may influence the lethality of acetaminophen.
Asunto(s)
Acetaminofén/efectos adversos , Ritmo Circadiano , Compuestos de Sulfhidrilo/metabolismo , Acetaminofén/metabolismo , Animales , Sistema Enzimático del Citocromo P-450/metabolismo , Glutatión/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , RatonesRESUMEN
Ondansetron, an antagonist of the serotonin type 3 (5-HT3) receptor, is indicated for the treatment of chemotherapy-induced emesis. This study compares the pharmacokinetics, especially the bioavailability, of an ondansetron 8-mg solution when administered intravenously, orally, to the colon via nasogastric intubation, and to the rectum using a retention enema. Six healthy, male volunteers received ondansetron infused into the colon during the first treatment period. These subjects then received the remaining three treatments in random order, with a minimum 1-week washout period between treatments. Serial plasma samples were obtained for up to 24 hr after dosing in each treatment period. Absolute bioavailability after the oral dosing, colonic infusion, and rectal administration averaged 71 +/- 14, 74 +/- 26, and 58 +/- 18%, respectively. These values were not significantly different (P > 0.05). Values of Tmax and Cmax were also not significantly different among the nonparenteral routes. Mean absorption half-lives were 0.66, 1.1, and 0.75 hr after the oral, colonic, and rectal administrations, respectively. These results indicate that ondansetron is well absorbed in the intestinal segments studied including the upper small intestine, the colon, and the rectum and that sustained-release and suppository formulations of ondansetron are feasible.
Asunto(s)
Ondansetrón/farmacocinética , Administración Oral , Administración Rectal , Adulto , Disponibilidad Biológica , Cromatografía Líquida de Alta Presión , Enema , Semivida , Humanos , Infusiones Intravenosas , Absorción Intestinal , Intubación Gastrointestinal , Masculino , Ondansetrón/administración & dosificación , Espectrofotometría UltravioletaRESUMEN
Recently, we reported that SPC-100270, a sphingosine derivative and inhibitor of protein kinase C (50-90 microM) in mixed micelle assays, reduced reperfusion injury resulting from hypoxia in a low-flow, reflow model of liver perfusion. Here we report that SPC-100270 has similar beneficial effects following liver transplantation in vivo. Rat liver transplantation was performed using nonarterial and rearterial techniques. Livers from syngenic rats were harvested surgically, prepared with vascular cuffs and a splint, and stored for 24 or 48 h in University of Wisconsin (UW) cold storage solution. Just prior to completion of vascular reconstruction, the organ was rinsed with 3 or 10 ml of Ringer's solution, vehicle, or a solution containing SPC-100270 (up to 500 microM). Following implantation surgery, low doses of SPC-100270 were ineffective at reducing both parenchymal and nonparenchymal cell death, yet significant (P < 0.05) reductions were observed with 500 microM. Further, nonparechnymal cell viability was improved nearly four fold by the drug. SPC-100270 (500 microM) tended to increase survival following 48 h cold storage in UW solution, but the improvement was not statistically significant. SPC-100270 also did not diminish carbon-centered free radical formation in transplanted livers from alcohol-treated rats. Collectively, these data support the hypothesis that pretreatment of donor livers with an inhibitor of protein kinase C is effective in vivo at reducing reperfusion injury, particularly to nonparenchymal cells, following orthotopic liver transplantation in the rat.
Asunto(s)
Hígado Graso/fisiopatología , Hígado Graso/cirugía , Supervivencia de Injerto/efectos de los fármacos , Trasplante de Hígado/fisiología , Proteína Quinasa C/antagonistas & inhibidores , Daño por Reperfusión/patología , Esfingosina/análogos & derivados , Esfingosina/farmacología , Adenosina , Alopurinol , Animales , Supervivencia Celular/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Femenino , Glutatión , Insulina , Trasplante de Hígado/métodos , Trasplante de Hígado/patología , Soluciones Preservantes de Órganos , Rafinosa , Ratas , Daño por Reperfusión/prevención & control , Trasplante IsogénicoRESUMEN
Safingol [(2S,3S)-2-amino-1,3-octadecanediol] potentiates the toxicity of doxorubicin (DOX) and cisplatin (CIS) against tumor cells in vitro and in vivo. The present studies were conducted in rats and dogs to evaluate safingol toxicity when administered i.v. as a single agent and to evaluate safingol's ability to potentiate the toxicity of established chemotherapeutic agents to normal tissues in vivo. In an escalating dose study, dogs were administered safingol i.v. at 5, 10, 20, 30, 40, and 75 mg/kg on Days 1 through 6. Necropsies were performed on Day 7. Red urine was observed at 10 mg/kg and higher. Icterus was observed following 40 mg/kg with additional signs of hypoactivity and anorexia occurring after 75 mg/kg. Clinical and microscopic pathology revealed marked hepatotoxicity, venous degeneration and necrosis at injection sites, and evidence of intravascular hemolysis. Doses of 5, 20, or 40 mg safingol/kg were utilized in single i.v. dose rat and dog studies. No evidence of adverse systemic toxicity was seen up to 20 mg/kg in either species [for rats: Cmax = 12,600 (males) or 17,133 (females) ng/ml, AUC = 3853 (males) or 4365 (females) ng x hr/ml; for dogs: Cmax = 2533 ng/ml, AUC = 2851 ng x hr/ml (no sex differences)]. Local effects of venous irritation or intravascular hemolysis were observed at all doses in rats and at 20 and 40 mg/kg in dogs. A dose of 40 mg/kg [for rats: Cmax = 31,233 (males) or 91,300 (females) ng/ml, AUC = 11,519 (males) or 18,620 (females) ng x hr/ml; for dogs: Cmax = 9033 ng/ml, AUC = 11,094 ng x hr/ml (combined sex)] was associated with clinical pathologic and renal histomorphologic changes considered consequent to intravascular hemolysis in both species, lethality and testicular toxicity in rats, and clinical biochemical changes indicative of hepatobiliary injury in dogs. Studies indicated that hemolysis occurred during infusion, was not caused by circulating levels of safingol, and was a function of dose concentration and vein of delivery. Safingol at 10 or 20 mg/kg was administered i.v. to rats 30-60 min prior to myelosuppressive i.v. doses of DOX, CIS, or cyclophosphamide (CYP). Hematology, plus renal function and morphology for CIS-treated animals, was assessed 4 and 14 days later.(ABSTRACT TRUNCATED AT 400 WORDS)